Efficacy and safety of Mim8 prophylaxis in adults and adolescents with hemophilia A with or without inhibitors: Phase 3, open-label, randomized, controlled FRONTIER2 study

Maria Elisa Mancuso M.D., Ph.D.
IRCCS Humanitas Research Hospital
Rozzano, Milan, Italy

Prophylaxis in hemophilia A continues to remain an area of rapid clinical advancement. Maria Elisa Mancuso, M.D., Ph.D., presents the results of the FRONTIER2 clinical trial, an open label randomized controlled study, aimed at evaluating the efficacy and safety of Mim8 in men and women with hemophilia A with or without inhibitors. Overall, 254 patients have been enrolled and treated with Mim8 either once every week or once every month, demonstrating superiority over on-demand or previous prophylaxis in reducing annualized bleeding rates.